title: Intravenous immunoglobulin enhances the killing activity and autophagy of neutrophils isolated from immunocompromised patients against multidrug-resistant bacteria.
abstract: Intravenous immunoglobulin (IVIG) is periodically administered to immunocompromised patients together with antimicrobial agents. The evidence that supports the effectiveness of IVIG is mostly based on data from randomized clinical trials; the underlying mechanisms are poorly understood. A recent study revealed that killing of multidrug-resistant bacteria and drug-sensitive strains by neutrophils isolated from healthy donors is enhanced by an IVIG preparation. However, the effectiveness of IVIG in immunocompromised patients remains unclear. The present study found that IVIG increased both killing activity and O2(-) release by neutrophils isolated from six patients receiving immune-suppressive drugs after hematopoietic stem cell transplantation (HSCT); these neutrophils killed both multidrug-resistant extended-spectrum β-lactamase-producing Escherichia coli (E. coli) and multidrug-resistant Pseudomonas aeruginosa (P. aeruginosa). Moreover, IVIG increased the autophagy of the neutrophils, which is known to play an important role in innate immunity. These results suggest that IVIG promotes both the killing activity and autophagy of neutrophils isolated from immunocompromised patients against multidrug-resistant bacteria.
authors.affiliation: Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan; Department of Clinical Laboratory, Kyoto University Hospital, Kyoto 606-8507, Japan.
authors.forename: Hidemasa
authors.initials: H
authors.lastname: Matsuo
authors.affiliation: Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Itoh
authors.affiliation: Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
authors.forename: Naoko
authors.initials: N
authors.lastname: Kitamura
authors.affiliation: Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Kamikubo
authors.affiliation: Department of Clinical Laboratory, Kyoto University Hospital, Kyoto 606-8507, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Higuchi
authors.affiliation: Department of Clinical Laboratory, Kyoto University Hospital, Kyoto 606-8507, Japan.
authors.forename: Shuichi
authors.initials: S
authors.lastname: Shiga
authors.affiliation: Department of Infection Control and Prevention, Kyoto University Hospital, Kyoto 606-8507, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ichiyama
authors.affiliation: Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
authors.forename: Tadakazu
authors.initials: T
authors.lastname: Kondo
authors.affiliation: Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
authors.forename: Akifumi
authors.initials: A
authors.lastname: Takaori-Kondo
authors.affiliation: Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan. Electronic address: adachiso@kuhp.kyoto-u.ac.jp.
authors.forename: Souichi
authors.initials: S
authors.lastname: Adachi
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001343:Autophagy / Q000187:drug effects / Q000276:immunology; D018920:Coculture Techniques; D024901:Drug Resistance, Multiple, Bacterial; D004926:Escherichia coli / Q000187:drug effects / Q000254:growth & development / Q000276:immunology; D005260:Female; D019337:Hematologic Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016867:Immunocompromised Host; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009504:Neutrophils / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D061251:Primary Cell Culture; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000254:growth & development / Q000276:immunology; D013481:Superoxides / Q000819:agonists* / Q000378:metabolism; D001618:beta-Lactamases / Q000096:biosynthesis
chemical_list: D000900:Anti-Bacterial Agents; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D013481:Superoxides; D001618:beta-Lactamases
keywords: Autophagy; Immunocompromised host; Intravenous immunoglobulin; Multidrug-resistant bacteria; Neutrophil